MASSACHUSETTS EYE AND EAR INFIRMARY
- Type
- Teaching hospital
- Where
- BOSTON, MA
- Medicare CCN
- 220075
- Received
- $1,528,189 in 43 records, 2022 ($794,301 general, $733,888 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
- Plan sponsor: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Lobbying client: MASSACHUSETTS EYE AND EAR INFIRMARY Fuzzy (name and state)
- Patent assignee: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
- Trademark owner: Massachusetts Eye and Ear Infirmary Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 16 | $794,301 |
| 2022 | Research payment | 27 | $733,888 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Bausch & Lomb Americas Inc. | 5 | $704,449 | 2022 |
| Alcon Research LLC | 3 | $274,000 | 2022 |
| Genentech, Inc. | 5 | $272,844 | 2022 |
| Biogen, Inc. | 6 | $116,402 | 2022 |
| Celgene Corporation | 1 | $100,000 | 2022 |
| Oyster Point Pharma, Inc. | 5 | $19,376 | 2022 |
| Medtronic, Inc. | 1 | $8,000 | 2022 |
| Inspire Medical Systems, Inc. | 4 | $7,315 | 2022 |
| MED-EL Corporation | 1 | $6,530 | 2022 |
| Optinose US, Inc. | 2 | $5,701 | 2022 |
| ABBVIE INC. | 1 | $5,000 | 2022 |
| Stryker Corporation | 1 | $3,000 | 2022 |
| Advanced Bionics, LLC | 2 | $2,180 | 2022 |
| Spark Therapeutics, Inc. | 1 | $1,837 | 2022 |
| Philips North America LLC | 1 | $1,200 | 2022 |
| EMD Millipore Corporation | 1 | $185 | 2022 |
| Grace Medical, Inc. | 1 | $135 | 2022 |
| Gyrus ACMI, Inc. | 2 | $32 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Royalty or License | 12 | $768,301 |
| Research payment | 27 | $733,888 |
| Grant | 2 | $15,000 |
| Space rental or facility fees (teaching hospital only) | 2 | $11,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Philips North America LLC | $1,200 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | WF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children | 2022 |
| 2022-12-06 | Alcon Research LLC | $82,000 | Research payment | Cash or cash equivalent | A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dr | 2022 | |
| 2022-11-23 | Gyrus ACMI, Inc. | $19 | Royalty or License | Cash or cash equivalent | DORNHOFFER INTERPOSITIONALPORP W TITANIUM CRADLE3 MM OVERALL LENGTH 2 MM FUNCT Device, Ear, Nose, Throat | 2022 | |
| 2022-11-14 | Bausch & Lomb Americas Inc. | $239,796 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2022 | |
| 2022-11-04 | Inspire Medical Systems, Inc. | $3,275 | Research payment | Cash or cash equivalent | Inspire Upper Airway Stimulation System Device, Neurology | PREDICTOR STUDY | 2022 |
| 2022-11-01 | Oyster Point Pharma, Inc. | $8,500 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-0 | 2022 | |
| 2022-11-01 | Genentech, Inc. | $2,812 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2022 |
| 2022-10-28 | ABBVIE INC. | $5,000 | Grant | Cash or cash equivalent | COMBIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-10-25 | Grace Medical, Inc. | $135 | Royalty or License (4 payments) | Cash or cash equivalent | OTOSHIELD PROTECTIVE BARRIER DRAPE Medical Supply, OTOLOGY | 2022 | |
| 2022-10-13 | Biogen, Inc. | $16,055 | Research payment | Cash or cash equivalent | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P | 2022 | |
| 2022-10-06 | Alcon Research LLC | $96,000 | Research payment | Cash or cash equivalent | A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dr | 2022 | |
| 2022-10-04 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2022 |
| 2022-10-04 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2022 |
| 2022-09-15 | Genentech, Inc. | $249,688 | Research payment | Cash or cash equivalent | Drug | PRE-CLINICAL09152022 | 2022 |
| 2022-08-23 | Biogen, Inc. | $50,000 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-08-14 | Bausch & Lomb Americas Inc. | $128,669 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2022 | |
| 2022-08-11 | Optinose US, Inc. | $795 | Research payment | Cash or cash equivalent | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 | |
| 2022-08-03 | Bausch & Lomb Americas Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Gyrus ACMI, Inc. | $13 | Royalty or License | Cash or cash equivalent | DORNHOFFER INTERPOSITIONALPORP W TITANIUM CRADLE3 MM OVERALL LENGTH 2 MM FUNCT Device, Ear, Nose, Throat | 2022 | |
| 2022-07-21 | Genentech, Inc. | $14,344 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2022 |
| 2022-07-13 | Medtronic, Inc. | $8,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MIDAS REX Device, High Speed Surgical Drills and Tools | 2022 | |
| 2022-07-06 | Oyster Point Pharma, Inc. | $715 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-0 | 2022 | |
| 2022-07-05 | Alcon Research LLC | $96,000 | Research payment | Cash or cash equivalent | A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dr | 2022 | |
| 2022-05-15 | Bausch & Lomb Americas Inc. | $177,813 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2022 | |
| 2022-05-13 | Inspire Medical Systems, Inc. | $150 | Research payment | Cash or cash equivalent | Inspire Upper Airway Stimulation System Device, Neurology | HOME STUDY | 2022 |
| 2022-04-20 | Advanced Bionics, LLC | $102 | Research payment | In-kind items and services | HIRES ULTRA CI HIFOCUS MS ELECTRODE Device, OTOLARYNGOLOGY | Development and assessment of listener-tailored CI programming | 2022 |
| 2022-04-13 | Spark Therapeutics, Inc. | $1,837 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2022 |
| 2022-03-23 | Advanced Bionics, LLC | $2,078 | Research payment | In-kind items and services | HIRES ULTRA CI HIFOCUS MS ELECTRODE Device, OTOLARYNGOLOGY | Development and assessment of listener-tailored CI programming | 2022 |
| 2022-02-18 | EMD Millipore Corporation | $185 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2022 | |
| 2022-02-14 | Bausch & Lomb Americas Inc. | $148,170 | Royalty or License | Cash or cash equivalent | VISUDYNE Drug, Ophthalmology | 2022 | |
| 2022-02-11 | Stryker Corporation | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CAPRI CORPECTOMY CAGE SYSTEM Device, SPINE | 2022 | |
| 2022-02-07 | Biogen, Inc. | $26,848 | Research payment | Cash or cash equivalent | An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno- | 2022 | |
| 2022-02-04 | Inspire Medical Systems, Inc. | $3,790 | Research payment | Cash or cash equivalent | Inspire Upper Airway Stimulation System Device, Neurology | HOME STUDY | 2022 |
| 2022-02-04 | Inspire Medical Systems, Inc. | $100 | Research payment | In-kind items and services | Inspire Upper Airway Stimulation System Device, Neurology | PEDIATRIC PAS STUDY | 2022 |
| 2022-01-31 | Oyster Point Pharma, Inc. | $10,000 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-0 | 2022 | |
| 2022-01-31 | Oyster Point Pharma, Inc. | $36 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-0 | 2022 | |
| 2022-01-28 | Celgene Corporation | $100,000 | Research payment | Cash or cash equivalent | Phase Ib Motolimod Pre Surgerical Biomarker SCCHN (VTX-2337-HN-001) (BMS Study Number: CA075-P01) | 2022 | |
| 2022-01-25 | Oyster Point Pharma, Inc. | $125 | Research payment | Cash or cash equivalent | A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-0 | 2022 | |
| 2022-01-20 | MED-EL Corporation | $6,530 | Research payment | In-kind items and services | ADHEAR Professional Kit Device, Bone Conduction System | ADHEAR in infants with Down Syndrome and minimal hearing loss | 2022 |
| 2022-01-14 | Biogen, Inc. | $11,648 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-01-14 | Biogen, Inc. | $9,975 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-01-14 | Biogen, Inc. | $1,875 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-01-12 | Optinose US, Inc. | $4,906 | Research payment | Cash or cash equivalent | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments